Vivos Therapeutics Inc (VVOS)
NASDAQHealth CareMedical - DevicesSnapshot 2026-11-04
$0.11+1.28%
Close 2026-11-04 · 1-day change
NASDAQHealth CareMedical - DevicesSnapshot 2026-11-04
QuarterlyIQ Insights · VVOS
How strong the business is — where it ranks within its sector on capital efficiency and cash generation, and how well management has been executing.
How management runs the business: capital, margins, balance sheet, and how reliably they guide and deliver.
A guidance track record builds as the company issues and delivers on guidance.
Priorities management has stated in recent disclosures, with status and evidence drawn from earnings calls, filings, and press releases.
Exhibit 99.1 Vivos Therapeutics Closes Acquisition of Stake in SOD Sciences and 50% Interest in Pseudohypoxia Test, Opening a Potential Path to Access More Than 325,000 New Patients Through the AHA C…
Stated in 1 of 2 supplied quarters. Management reported: “While our operating loss reflects the upfront investments in this new model, we believe these actions, together with recent significant cost-savings initiatives and strengthened capital structure, position Vivos to drive higher top-line growth, better contribution margins, and a clear path toward our goal of cash flow positive operations by end of this year.”” “Management believes that, if definitive agreements with AHA are executed and the channel is implemented as contemplated, the AHA channel could represent a meaningful, potentially multi-million dollar, OSA sleep testing revenue opportunity for Vivos beginning in 2027, with limited capital and staffing outlays from Vivos.” Revenue was $3.824 million in 2025-Q4.
Each factor is a parallel diagnostic with a clear read of what it shows and how names like it have historically fared. Never aggregated into a single score.
Operating income rose in 1 of the last 3 quarter-over-quarter moves. Historically, Health Care names rated neutral grew net income 51% of the time over the next year (vs 41% for the rest of the cohort, n=13498).
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
“Vivos’ new business strategy is focused on contractual alliances with and outright acquisitions of sleep specialty medical providers, sleep testing centers and other similar entities.”
While our operating loss reflects the upfront investments in this new model, we believe these actions, together with recent significant cost-savings initiatives and strengthened capital structure, po…
Stated in 1 of 2 supplied quarters. Management reported: “While our operating loss reflects the upfront investments in this new model, we believe these actions, together with recent significant cost-savings initiatives and strengthened capital structure, position Vivos to drive higher top-line growth, better contribution margins, and a clear path toward our goal of cash flow positive operations by end of this year.”” “Authorized 50,000,000 shares; no shares issued and outstanding - - Common Stock, $0.0001 par value per share.” Operating income was $-6.377 million in 2025-Q4.
“While our operating loss reflects the upfront investments in this new model, we believe these actions, together with recent significant cost-savings initiatives and strengthened capital structure, po…”
While our operating loss reflects the upfront investments in this new model, we believe these actions, together with recent significant cost-savings initiatives and strengthened capital structure, po…
Stated in 1 of 2 supplied quarters. Management reported: “While our operating loss reflects the upfront investments in this new model, we believe these actions, together with recent significant cost-savings initiatives and strengthened capital structure, position Vivos to drive higher top-line growth, better contribution margins, and a clear path toward our goal of cash flow positive operations by end of this year.”” “Authorized 50,000,000 shares; no shares issued and outstanding - - Common Stock, $0.0001 par value per share.” Gross profit was $2.986 million in 2025-Q4.
“While our operating loss reflects the upfront investments in this new model, we believe these actions, together with recent significant cost-savings initiatives and strengthened capital structure, po…”
Exhibit 99.1 Vivos Therapeutics Closes Acquisition of Stake in SOD Sciences and 50% Interest in Pseudohypoxia Test, Opening a Potential Path to Access More Than 325,000 New Patients Through the AHA C…
Stated in a supplied disclosure. Management reported: “Management believes that, if definitive agreements with AHA are executed and the channel is implemented as contemplated, the AHA channel could represent a meaningful, potentially multi-million dollar, OSA sleep testing revenue opportunity for Vivos beginning in 2027, with limited capital and staffing outlays from Vivos.” “Nasdaq Stockholders’ Equity Requirement As previously disclosed, in April 2026 the Company received a notice from The Nasdaq Stock Market LLC that it did not satisfy the minimum stockholders’ equity requirement of $2.5 million for continued listing under Nasdaq Listing Rule 5550(b)(1).”
R. Kirk Huntsman, Chairman and Chief Executive Officer of Vivos, stated, “We are pleased to receive the compliance letter from Staff indicating that we are in compliance with Nasdaq’s Stockholders’ E…
Stated in a supplied disclosure. Management reported: “R. Kirk Huntsman, Chairman and Chief Executive Officer of Vivos, stated, “We are pleased to receive the compliance letter from Staff indicating that we are in compliance with Nasdaq’s Stockholders’ Equity Standard required for continued listing on the Nasdaq Capital Market.” “Nasdaq Stockholders’ Equity Requirement As previously disclosed, in April 2026 the Company received a notice from The Nasdaq Stock Market LLC that it did not satisfy the minimum stockholders’ equity requirement of $2.5 million for continued listing under Nasdaq Listing Rule 5550(b)(1).”
Over the trailing year it converted 0.87x of net income into operating cash flow.
Not enough signal yet.
Not enough signal to read sensitivity to the broad stock market, the US dollar, Fed net liquidity, real (inflation-adjusted) rates, long-term interest rates (low R² over the window).
41 material management or governance events in the past 24 months, led by capital-allocation actions. Historically, Health Care names rated volatile grew net income 45% of the time over the next year (vs 45% for the rest of the cohort, n=10076).
Not investment advice. As of 2026-11-04.